Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia
NCT ID: NCT03679949
Last Updated: 2024-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
26 participants
INTERVENTIONAL
2019-04-01
2022-12-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Participants will receive 0 mg oxycodone (oral) and placebo cannabis (vaporized)
Placebo
Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone
Oxycodone
Participants will receive 2.5 mg oxycodone (oral) and placebo cannabis (vaporized)
Oxycodone
Oxycodone, 2.5 mg
Placebo
Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone
Cannabis (THC:CBD = ~1:0)
Participants will receive 0 mg oxycodone (oral) and cannabis with high THC concentrations (vaporized)
Cannabis (THC:CBD = ~ 1:0)
Cannabis with high THC concentration and negligible CBD concentrations
Placebo
Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone
Cannabis (THC:CBD = ~ 0:1)
Participants will receive 0 mg oxycodone (oral) and cannabis with high CBD concentrations (vaporized)
Cannabis (THC:CBD = ~ 0:1)
Cannabis with high CBD concentration and negligible THC concentrations
Placebo
Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone
Cannabis (THC:CBD = ~ 1:1)
Participants will receive 0 mg oxycodone (oral) and cannabis with equal CBD and THC concentrations (vaporized)
Cannabis (THC:CBD = ~ 1:1)
Cannabis with equivalent CBD and THC concentrations
Placebo
Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone
Cannabis (THC:CBD = ~1:0) + Oxycodone
Participants will receive 2.5 mg oxycodone (oral) and cannabis with high THC concentrations (vaporized)
Oxycodone
Oxycodone, 2.5 mg
Cannabis (THC:CBD = ~ 1:0)
Cannabis with high THC concentration and negligible CBD concentrations
Cannabis (THC:CBD = ~ 0:1) + Oxycodone
Participants will receive 2.5 mg oxycodone (oral) and cannabis with high CBD concentrations (vaporized)
Oxycodone
Oxycodone, 2.5 mg
Cannabis (THC:CBD = ~ 0:1)
Cannabis with high CBD concentration and negligible THC concentrations
Cannabis (THC:CBD = ~ 1:1) + Oxycodone
Participants will receive 2.5 mg oxycodone (oral) and cannabis with equal concentrations of THC and CBD (vaporized)
Oxycodone
Oxycodone, 2.5 mg
Cannabis (THC:CBD = ~ 1:1)
Cannabis with equivalent CBD and THC concentrations
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxycodone
Oxycodone, 2.5 mg
Cannabis (THC:CBD = ~ 1:0)
Cannabis with high THC concentration and negligible CBD concentrations
Cannabis (THC:CBD = ~ 0:1)
Cannabis with high CBD concentration and negligible THC concentrations
Cannabis (THC:CBD = ~ 1:1)
Cannabis with equivalent CBD and THC concentrations
Placebo
Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Previous cannabis use
* Previous opioid use
* Urine test positive for recent cannabis use
* Being able to perform all study procedures
* Currently practicing an effective form of birth control (women only)
Exclusion Criteria
* Report regular illicit drug use
* If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process revealed any significant illness
21 Years
53 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
New York State Psychiatric Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Caroline A. Arout, Ph.D.
Research Scientist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Caroline A Cooper, PhD
Role: PRINCIPAL_INVESTIGATOR
New York Psychiatric Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New York State Psychiatric Institute
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
7647
Identifier Type: -
Identifier Source: org_study_id